Navigation Links
Hemophilia Pipeline Overview - Once-a-week prophylaxis may soon become a reality
Date:12/13/2012

NEW YORK, Dec. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality 

http://www.reportlinker.com/p01055538/Hemophilia-Pipeline-Overview-–-Once-a-week-prophylaxis-may-soon-become-a-reality.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology 

Among the products for hemophilia A and B that are likely to reach the market within the next 4 years are modified recombinant factor replacements that could reduce injection frequencies significantly, making once-a-week prophylaxis a reality.Assess key pipeline products with regards to current gold-standard therapies.Identify the prospects faced by next-generation products in this niche market.Review and profile current key pipeline hemophilia A and B factor replacement products.Assess current unmet needs and challenges faced by pipeline products.

The most important unmet need is a longer half-life for clotting factors so that daily intravenous injections are no longer necessary. Moving from daily to weekly or fortnightly injections would improve patients' quality of life enormously.

Since longer clotting factor half-life is the major unmet need in hemophilia treatment, Datamonitor believes that novel recombinant compounds can only gain significant market share by either addressing the lack of long-acting recombinant factor IX therapeutics or by addressing the need for more competitively priced recombinant products.

Economy of scale plays a role when producing a biologic compound cost-effectively and established companies will have an advantage in this area; having the right infrastructure, production facilities, marketing channels, and sales force are important factors that will determine whether a company can successfully enter the hemophilia market.

Datamonitor's up to date key pipeline hemophilia A and B therapeutics profiles includes the latest clinical data and industry developments.Understand the most pressing unmet needs in hemophilia and how current pipeline products can gain significant market share by addressing them.Compare pipeline products with current gold-standard treatments and assess what they will have to do to deliver growth.

OVERVIEW

Catalyst

Summary

Clinical Pipeline Overview

A handful of key players dominate the market

Gene therapy looks hopeful but market entry is still not predicted for this decade

Current Gold-Standard Product Profiles

Kogenate FS (FVIII recombinant; Bayer): the gold-standard hemophilia A therapy

BeneFIX (FIX recombinant; Pfizer): the gold-standard hemophilia B therapy

Target product profile versus current level of attainment

Key Factor VIII Pipeline Products

NN7008 (turoctocog alfa; Novo Nordisk)

BIIB 031 (rFVIIIFc; Biogen Idec)

NN7088 (rFVIII, glycopegylated; Novo Nordisk)

BAY-94-9027 (recombinant PEGylated factor VIII; Bayer)

Clinical and commercial attractiveness for key hemophilia A pipeline products

Key Factor IX Pipeline Products

BAX 326 (recombinant PEGylated factor IX; Baxter)

CSL654 (rFIX-albumin fusion; CSL Behring)

BIIB 029 (rFIXFc; Biogen Idec)

NN7999 (rFIX, glycoPEGylated; Novo Nordisk)

Clinical and commercial attractiveness for key hemophilia B pipeline products

Bibliography

Journal articles and online sources

Appendix

Methodology

Datamonitor drug assessment for clinical and commercial attractiveness

TABLES

Table: Clinical pipeline key drugs for hemophilia A and B, November 2012

Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012

Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012

Table: Kogenate FS (rFVIII; Bayer) and BeneFIX (rFIX; Pfizer) vs the target product profile in previously treated patients, 2012

Table: Key events in the clinical development of NN7008 (turoctocog alfa; Novo Nordisk), 2012

Table: Key events in the clinical development of BIIB 031 (rFVIIIFc; Biogen Idec), 2012

Table: Key events for the clinical development of NN7088 (Novo Nordisk), 2012

Table: Key events for the clinical development of BAY-94-9027 (Bayer), 2012

Table: Key events for the clinical development of BAX 326 (Baxter), 2012

Table: Key events for the clinical development of CSL654 (CSL Behring), 2012

Table: Key events for the clinical development of BIIB 029 (rFIXFc; Biogen Idec), 2012

Table: Key events for the clinical development of NN7999 (Novo Nordisk), 2012

FIGURES

Figure: Clinical and commercial attractiveness for key hemophilia A pipeline drugs vs comparator Kogenate FS (rFVIII; Bayer), 2012

Figure: Breakdown of clinical and commercial attractiveness attributes for key hemophilia A pipeline drugs, 2012

Figure: Launch timeline for key hemophilia A pipeline drugs, 2012

Figure: Clinical and commercial attractiveness for key hemophilia B pipeline drugs vs comparator BeneFIX (rFIX; Pfizer), 2012

Figure: Breakdown of clinical and commercial attractiveness attributes for key hemophilia B pipeline drugs, 2012

Figure: Launch timeline for key hemophilia B pipeline drugs, 2012

Companies Mentioned

Arriva plc, CSL Behring, Hutchison 3G UK Limited, Imperial Tobacco Group PLC, Ipsen S.A., Nektar Therapeutics, Telstra Corporation Limited

To order this report:

Pathology Industry: Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality  

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk introduces HemaGo, a mobile application to track hemophilia treatment, bleeding episodes and life events
2. Bayers Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
3. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
4. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
5. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
6. Bausch + Lomb Product, Platform and Pipeline Innovations on Display at the Annual Meeting of the American Academy of Ophthalmology
7. Chronic Heart Failure (CHF) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
8. Neurostimulation Devices Market to 2018 - Technological Advances and Robust Pipeline with Multi-Indication Potential and Non-Invasive Therapies to Drive Growth
9. Epigenetics R&D Pipeline - Histone Deacetylases (HDACs) Offer the Most Promising Targets and Outnumber Other Classes of Epigenetic Targets
10. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
11. Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), ... Neurology and Orphan Diseases, today announced that President & CEO ... conferences: SeeThru Equity MicroCap Conference   ... City , NY When: Tuesday, May 31 st ... Where: Grand Hyatt Hotel, 109 East 42 nd ...
(Date:5/26/2016)... -- According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - ... valued at US$ 5.89 Bn in 2014 and is anticipated ... 2023 to reach US$ 7.99 Bn in 2023. ... free drug delivery devices and the market is estimated based ...
(Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of ... Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who ... this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program ...
(Date:5/27/2016)... ... 27, 2016 , ... With over 60 percent of acute stroke survivors being ... product to aid in the rehabilitation process has steadily increased. Ekso Bionics had been ... hemiplegia due to stroke. , Ekso Bionics has now received clearance from the U.S. ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
Breaking Medicine News(10 mins):